Company Information & Drug Savings for Seagen Medications
Seagen (formerly Seattle Genetics), now part of Pfizer, pioneered antibody-drug conjugate (ADC) technology for cancer treatment. Key products include Adcetris (brentuximab vedotin) for Hodgkin lymphoma and other blood cancers, Padcev (enfortumab vedotin) for bladder cancer, and Tukysa (tucatinib) for HER2-positive breast cancer. Seagen’s ADC expertise continues advancing targeted cancer therapies through Pfizer.
How to Contact Seagen
Phone
1-425-527-4000Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
Experienced a Side Effect?
Report to Yellow Card (UK) or MedWatch (US)
